Completed PHASE3 INTERVENTIONAL 3-arm NCT00422383

A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)

A Randomized, Double-blind Study to Evaluate the Effect of Various Re-treatment Regimens of MabThera in Combination With Methotrexate on Treatment Response in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.

Sponsor: Hoffmann-La Roche

Conditions Rheumatoid Arthritis

Interventions rituximab [MabThera/Rituxan]

Updated 6 times since 2017 Last updated: Apr 16, 2015 Started: Feb 28, 2006 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Arenzano, Italy , Auckland, New Zealand , Bad Nauheim, Germany , Bangkok, Thailand , Barcelona, Spain , Barnsley, United Kingdom , Beijing, China , Birmingham, United Kingdom , Bois-Guillaume, France and 75 more locations